Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

onday, December 9, 5:00 pm CT, 393-394
  • Oral presentation: Myeloma: Therapy, excluding Transplantation II
  • Abstract # 687
  • Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates of MRD Negativity in Newly Diagnosed Multiple Myeloma (MM) Patients

    • Dr. Neha Korde, Multiple Myeloma Section, National Cancer Institute, National Institutes of Health
    • Monday, December 9, 3:30 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation: Treatment Options for Newly Diagnosed Multiple Myeloma Patients
    • Abstract # 538

    Serum Heavy-Light Chains (HLC) and Free Light Chains (FLC) As Predictors For Early CR In Newly Diagnosed Myeloma Patients Treated With Carfilzomib, Lenalidomide, and Dexamethasone (CRd)

    • Dr. Manisha Bhutani, Multiple Myeloma Section, National Cancer Institute, National Institutes of Health
    • Monday, December 9, 7:30 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation: Advances in Multiple Myeloma and Plasma Cell Leukemia
    • Abstract # 762

    Phase I/II Dose Expansion of a Multi-Center Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma

    • Dr. Jatin Shah, The University of Texas MD Anderson Cancer Center
    • Monday, December 9, 5:45 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation II
    • Abstract # 690

    Carfilzomib, Rituximab and Dexamethasone (CaRD) is highly active and offers a neuropathy sparing approach for proteasome-inhibitor based the
    '/>"/>

    SOURCE Onyx Pharmaceuticals, Inc.; Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
    2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
    3. Amgen Announces 2012 First Quarter Dividend
    4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
    5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
    6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
    7. Amgen to Acquire Micromet
    8. Amgen to Present at the Leerink Swann Global Healthcare Conference
    9. Amgen Announces 2012 Third Quarter Dividend
    10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
    11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/22/2014)... , July 22, 2014 Hussey Copper ... MD-Cu 29 antimicrobial copper announces Pullman Regional Hospital,s ... first EPA-registered antimicrobial solid touch surface, at a nominal ... of MRSA, E-coli and other bacteria within 2 hours of ... protecting against bacteria and infectious diseases in its facilities. ...
    (Date:7/22/2014)... Md. , July 22, 2014  United ... today that it will release its second quarter ... July 29, 2014. United Therapeutics will ... 2014, at 9:00 a.m. Eastern Time.  The teleconference ... dialing 1-970-315-0533.  A rebroadcast of the teleconference will ...
    (Date:7/22/2014)... 2014 Dr. Williams says, “Bush has ... recognized that the greatest health care system in the ... needlessly deadly while trying to serve the public. Unfortunately, ... to transform an enormous system that none of them ... his continuing series of Open Letters ( http://is.gd/wdU2CM ) ...
    (Date:7/21/2014)... The yield so far is small, but chemists ... solution-based mineral substitution process to make a precursor to ... and alternative energy devices. , A paper describing the ... 21 issue of the journal Inorganic Chemistry , ... inorganic and nuclear chemistry fields. The paper was chosen ...
    Breaking Biology Technology:Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2Oregon chemists eye improved thin films with metal substitution 2
    ... , SEATTLE, Aug. 5 ... Murray, M.D., Ph.D. as Vice President of Clinical Development. ... at Omeros, and currently is leading the ongoing clinical ... the Company,s lead candidate being evaluated in a Phase ...
    ... The FIME 2009 ... John Rizvi will deliver a presentation titled, "Preservation of Legal Rights in Medical Innovations" at ... ... 2009 at 1:00 PM, attorney John Rizvi will deliver a presentation titled, "Preservation of Legal ...
    ... to develop organic solar cells that can be produced easily ... to generate electricity. But a major obstacle is coaxing ... the nanoscale (tinier than 2-millionths of an inch) to be ... to develop cells made from low-cost plastics that will transform ...
    Cached Biology Technology:Omeros Appoints New Vice President of Clinical Development 2Patent Attorney John Rizvi Speaks at FIME International Medical Expo 2Plastics that convert light to electricity could have a big impact 2Plastics that convert light to electricity could have a big impact 3
    (Date:7/22/2014)... of Standards and Technology (NIST), working with the ... for analyzing biological cells and tissues based on ... is an advanced form of the widely used ... that are 10,000 times stronger than obtained from ... obtained from comparable "coherent Raman" instruments, and uses ...
    (Date:7/22/2014)... as disease causing agents, some viruses can perform ... shape the world we live in today, according ... of Microbiology. , "Viruses participate in essential Earth ... planet, from contributing to biogeochemical cycles, shaping the ... Marilyn Roossinck of Pennsylvania State University, a member ...
    (Date:7/22/2014)... Stem cells offer much promise for treating damaged organs ... survival is poor, limiting their effectiveness. New methods are ... optimize their therapeutic function after transplantation, as described in ... a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ... Open Access website . , In ...
    Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Report on viruses looks beyond disease 2
    ... key to the blinding effects of diabetic retinopathy is ... Georgia researchers said. Interleukin-6, known to contribute ... helps ignite inflammation of the retina, a first step ... blindness is working-age adults, MCG researchers reported online in ...
    ... of dollars each year on exotic smelling perfumes and lotions ... a new study in Psychological Science , a journal ... be the best way to capture a potential mate,s attention. ... habits: Animal studies have shown that male testosterone levels are ...
    ... Malaga have created the ,Inventory of Daily Stressors, a ... physical appearance, taking part in numerous extracurricular activities and ... that increase the risk of suffering from childhood stress. ... to assess daily stress amongst schoolchildren", Mara Victoria Trianes, ...
    Cached Biology News:Discovery points toward anti-inflammation treatment for blinding disease 2A new method to measure childhood stress 2